Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms BOSTON
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 08 Nov 2018 According to a Karyopharm Therapeutics media release, the company is on track to complete enrolment in this trial by the end of 2018, with top-line data anticipated at the end of 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 28 Aug 2018 According to a Karyopharm Therapeutics media release, assuming a positive outcome, Karyopharm plans to use the results from the BOSTON study to support an application for full approval in the U.S.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top